Alvotech: BofA Initiates Buy Rating as Biosimilar Launch Cycle Begins
FDA clears Reykjavik plant as biosimilar launches drive commercial growth.
FDA clears Reykjavik plant as biosimilar launches drive commercial growth.
Wolfe Research upgrades Janux Therapeutics to Outperform with a $23 target. Q4 autoimmune data for JANX011 cited as key catalyst, 32% upside.
Morgan Stanley initiates Q32 Bio at Overweight ($34 target) as bempikibart matches JAK efficacy in alopecia areata while offering cleaner safety, less monitoring and durability.
Truist restarts Solid Biosciences at Buy/$20. JPMorgan backs Stoke Therapeutics at Overweight/$40. Cash into 2028.
Immunocore’s Kimmtrak hit ~$400M in 2025 sales with strong 2026 momentum. Solid cash, advancing Phase 3 trials, and Wall Street Buy ratings signal further upside.
Cantor Fitzgerald starts coverage of Nuvation Bio at Overweight, citing a low-risk oncology story with upside from Ibtrozi and safusidenib.